AbbVie Submits EMA Application For Skyrizi Subcutaneous Induction In Adult Crohn's Disease
ABBV•AbbVie submits EMA application for Skyrizi Crohn's disease use
Aug. 27 (Reuters) - AbbVie Inc. ABBV.N:
- AbbVie submits regulatory application to the European Medicines Agency for Skyrizi® (risankizumab) subcutaneous induction for adults with moderately to severely active Crohn's disease
- AbbVie submits regulatory application to the European Medicines Agency for Skyrizi® (risankizumab) subcutaneous induction for adults with moderately to severely active Crohn's disease
